Trial · NCT02987257
NATIENS: Optimal Management and Mechanisms of SJS/TEN
NCT02987257, Phase 3, Completed, Vanderbilt University Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. NATIENS: Optimal Management and Mechanisms of SJS/TEN. Trials, record NCT02987257. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02987257
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- NATIENS: Optimal Management and Mechanisms of SJS/TEN
- NCT number
- NCT02987257
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 2 participants, actual
- Lead sponsor
- Vanderbilt University Medical Center
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
- Interventions
- Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
- First posted
- 2016-12-08
- Last updated
- 2025-12-17
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to complete re-epithelialization | up to 4 weeks | Patients will be assessed by two independent raters (burn surgeons, dermatologists, wound care experts) to determine the day of full re-epithelialization. For disagreements on the day of re-epithelialization the case with supporting photographs will be referred to an independent adjudication committee comprised of a minimum of three experts (a burn surgeon, dermatologist, wound care expert). In the instance of death will be the maximum period of re-epithelialization (21 days + 1) |
| Secondary | Time to halting of progression of SJS/TEN skin disease | up to 4 weeks | Progression will be considered significant if there are any new blistering lesions or any new detached or detachable skin. |
| Secondary | Mortality | up to 1 year | Number of participants with mortality at 30 days, 3 months and 1 year |
| Secondary | Mortality | up to 4 weeks | Number of participants with Actual mortality versus expected mortality for each SCORTEN risk |
| Secondary | Ocular involvement | up to 1 year or study outcome | Time to cessation of acute ocular involvement acutely then extent of ocular involvement at follow-up will be assessed by two independent ophthalmology experts. Will be tracked by photography |
| Secondary | Infections | up to 4 weeks | Incidence of nosocomial infections |
| Secondary | Hospital length of stay | up to 4 weeks | Duration of time in hospital |
| Secondary | Proportion of patients with Adverse events due to assigned treatment arm | up to 4 weeks | Adverse events due to assigned treatment arm |
| Other | Granulysin, IL-15 and other cytokine measurements | up to 1 year or study outcome | Featured exploratory secondary outcome measuring difference overtime within an individual as well as differences between treatment arms at various time measurements. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02987257
GET https://conductscience.org/api/trials/v1/NCT02987257/registered